Xanthohumol

Phase 2Small molecule

NNational University of Natural Medicine

Xanthohumol is one of 68 small molecule programs targeting Crohn's Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Crohn's DiseaseActive, not recruiting

MetabolismActive, not recruiting

Crohn's DiseasePhase 2

Active, not recruiting

MetabolismPhase 1

Active, not recruiting

Competition

Competitive Landscape

67 competitors in Crohn's Disease

#DrugCompanyPhaseTrials

Remicade

Johnson & Johnson

Approved

27 2

Stelara

Johnson & Johnson

Approved

22 3

Entyvio

Takeda

Approved

14 4

Humira

RRanbaxy Laboratories Limited

Approved

22 5

Omvoh

Eli Lilly

Approved

7 6

Trexall

Jazz Pharmaceuticals

Approved

1 7

Lialda

Rocaltrol

Mycobutin

Opzelura

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Metabolism1 trial

Xanthohumol Metabolism and Signature

Active, not recruiting·NNational University of Natural Medicine·Phase 1·NCT03735420·30 enrolled

Crohn's Disease1 trial

A Phase 2 Clinical Trial: Xanthohumol Metabolism and Signature (XMaS) in Crohn's Disease

Active, not recruiting·NNational University of Natural Medicine·Phase 2·NCT04590508·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Xanthohumol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Xanthohumol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Xanthohumol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National University of Natural Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational University of Natural Medicine

Xanthohumol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Metabolism1 trial

Crohn's Disease1 trial

References

Drug Info

Quick Facts

Related News